Pharmafile Logo
Pharmafocus logo
Advanced Search

ADHD

Showing 15 posts of 37 posts found.

shutterstock_159488225

Alcobra axes ADHD drug after Phase 3 failure

January 18, 2017
Research and Development ADHD, Alcobra, metadoxine

Israeli-based firm Alcobra is to pull the plug on its experimental attention deficit hyperactivity disorder (ADHD) drug metadoxine after it …

News
shire_image_4

Shire says trial drug for ADHD shows positive results

June 30, 2016
Research and Development, Sales and Marketing ADHD, Shire, US FDA, drug trial, regulation

UK drugmaker Shire plc (LSE: SHP) said its trial drug to treat Attention-Deficit/Hyperactivity Disorder (ADHD) showed positive topline results.  Philip …

News
shire_image_4

Shire launches long-acting ADHD drug in UK

March 9, 2016
Sales and Marketing ADHD, Shire

Shire has launched its long-acting ADHD drug Intuniv (guanfacine) in the UK, for children and adolescents aged 6-17. The treatment …

News
Project EVO

Digital software shows benefit in ADHD trial

October 30, 2015
Medical Communications ADHD, Akili, PureTech Health, attention deficit hyperactivity disorder, digital tech

A pilot study of a digital health technology designed to improve symptoms of attention deficit hyperactivity disorder (ADHD) in children …

News
Shire

Shire ADHD treatment Intuniv gets EU approval

September 21, 2015
Sales and Marketing ADHD, Shire, attention deficit hyperactivity disorder, intuniv

The European Commission has granted marketing authorisation for Shire’s Intuniv for the treatment of ADHD in children.  Intuniv (guanfacine hydrochloride prolonged …

News
Shire image

Shire plots new ADHD drug approval

April 7, 2015
Sales and Marketing ADHD, FDA, SHP465, Shire, Vyvanse, clinical trials, paediatrics

Shire is launching a new clinical trial as part of its FDA submission for a potential ADHD treatment. The company …

News
Shire image

Shire delivers record revenues

February 16, 2015
Sales and Marketing ADHD, AbbVie, Shire, Viropharma, Vyvanse, intuniv, lialda

Shire has posted strong growth in its full-year results, showing that the company is faring well even after the collapse …

News
Shire image

Shire drug approved for binge eating disorder

February 2, 2015
Sales and Marketing ADHD, FDA, Shire, Vyvanse, binge, eating, lisdexamfetamine dimesylate, obesity

Shire has become the first company to gain FDA approval for a treatment for binge eating disorder (BED) in adults …

News
abbvie image

AbbVie a step closer to Shire takeover

July 14, 2014
Sales and Marketing ADHD, AbbVie, Abbott, Humira, Shire, hep C, takeover

Shire is recommending a new offer from suitor AbbVie that could finally see the US giant merge with the Dublin-based …

News
Shire image

AbbVie spells out Shire benefits

June 26, 2014
Sales and Marketing ADHD, AbbVie, Abbott, Humira, Shire, merger

AbbVie has spelt out exactly why it believes that Shire should accept its $46.5 billion bid. The US firm wants …

News
FDA image

FDA given $20 million for generic testing

February 24, 2014
Manufacturing and Production, Sales and Marketing ADHD, FDA, generics, hamburg

The FDA has been given $20 million to help it assess generic treatments, a group of drugs that makes up …

News
Shire HQ

Shire’s Vyvanse could bring in new revenue

February 14, 2014
Medical Communications, Research and Development, Sales and Marketing ADHD, Shire, Vyvanse, binge eating, generics

News
Shire image

Shire ADHD drug for UK

February 14, 2013
Sales and Marketing ADHD, Shire, Vyvanse, elvanse

Shire’s attention-deficit hyperactivity disorder (ADHD) drug Elvanse has been given the go-ahead for use in the UK. Elvanse (lisdexamfetamine dimesylate), …

News
Shire image

Shire pays Impax $48 million

February 12, 2013
Sales and Marketing ADHD, Adderall, Impax, Shire

Shire has paid $48 million to settle a long-running legal spat with Impax Laboratories over Shire’s supply of an authorised …

News

Pfizer buys NextWave Pharmaceuticals

October 23, 2012
Sales and Marketing ADHD, Pfizer, Qullivant, nextwave

Pfizer is to acquire NextWave Pharmaceuticals by the end of the year in a deal that could be worth $680 …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025